ClinicalTrials.gg
TerminatedNCT03948178REFALS-ESUpdated Mar 9, 2023Results posted

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

A Phase 3 interventional study of Levosimendan in Amyotrophic Lateral Sclerosis, sponsored by Orion Corporation, Orion Pharma. Terminated at 79 sites in 14 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2023-03-09.

Sponsored by Orion Corporation, Orion Pharma · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
This was an open label extension for patients completing the REFALS study (3119002; NCT03505021). Study 3119002 showed lack of efficacy of ODM109 so the sponsor decided to terminate this study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
227
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
39th of 307
227 · median 33
Started
2019
with 19 others
Phase 3
30 of 440
3 open now
Registered
238th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 39th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2019, is one of 30 in phase 3, and was the 238th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan. The study will also provide more information about long-term safety and effectiveness of oral levosimendan in patients with ALS.

This is an open-label study, so that all eligible subjects that complete the double-blind REFALS study (48-weeks of treatment) will have the opportunity to receive oral levosimendan treatment. The primary objective, in addition to continuing treatment for subjects enrolled in the REFALS study, is to evaluate long-term safety of oral levosimendan in ALS patients. Another important objective is to explore long-term effectiveness of oral levosimendan in the treatment of patients with ALS.

This study is open only to patients taking part in the REFALS study.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written or verbal (IC) for participation in the study
  • Subjects who completed 48 weeks of treatment according to the REFALS study protocol
  • Able to swallow study treatment capsules at the time of completing 48 weeks dosing in the REFALS study

Exclusion criteria

Exclusion Criteria:

  • Development (or significant worsening from baseline of the REFALS study) of serious cardiovascular disease (e.g.: myocardial infarction, heart failure, arrhythmia, stroke, or second or third degree atrioventricular (AV) block)
  • Pulse/heart rate repeatedly >100 bpm after 5-minute rest at baseline. If the pulse/heart rate is >100 bpm in the first recording, then a second recording must be done after another 5 min rest to confirm pulse/heart rate >100 bpm
  • Systolic blood pressure (SBP) \<90 mmHg
  • Severe renal impairment ( \< 30ml/min or creatine >170 µmol/l at 48 week visit of the REFALS study, or on dialysis
  • Severe hepatic impairment at the discretion of the investigator
  • Women of reproductive age without a negative pregnancy test and without a commitment to using a highly effective method of (e.g.: oral hormonal contraceptive associated with inhibition of ovulation, intrauterine devices and long acting progestin agent), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included
  • Subject judged to be actively suicidal by the investigator
  • Any other clinical significant cardiovascular, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
227 participants (actual)

Study arms

  • Experimental
    Levosimendan

    Oral Levosimendan; Levosimendan 1mg capsules for oral administration, once to twice a day, continued as long as clinically beneficial. The total study duration is up to 3 years.

    Drug: Levosimendan

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events Recording

    Adverse Events as subject counts and proportions (%) of subject per Adverse Event

    Time frame: From signing informed consent until 14-25 days after the last study treatment for all patients, an average of 23.5 weeks.

  2. Pulse/Heart Rate Assessment

    Actual values and changes from baseline in supine pre-dose pulse/heart rate were summarised using descriptive statistics .

    Time frame: Change in pulse and heart rate(from ECG recording) from Baseline, week 2, week 4, week 6 (pulse rate only), Month 3, Month 6, end of study (subject's last visit, 2-48 weeks after study entry)

  3. 12-lead Electrocardiogram Assessments

    Summarisation of any abnormal 12-lead ECG findings using descriptive statistics.

    Time frame: Baseline, week 2, week 4, month 3, month 6, end-of-study(subject's last visit, 2-48 weeks after study entry)

Secondary outcomes

  1. Disease Progression

    Count of study withdrawals due to disease progression

    Time frame: From Baseline through study completion(subject's last visit, 2-48 weeks after study entry)

  2. Supine Slow Vital Capacity (SVC)

    Change from baseline in supine and sitting SVC (all devices) through to the end of the study, expressed as a % of predicted normal

    Time frame: The change from Baseline, week 2, week 4, month 3, month 6, end-of-study (subject's last visit, 2-48 weeks after study entry)

  3. Revised ALS Functional Rating Scale (ALSFRS-R)

    ALSFRS-R scale contains 3 parameters related to respiratory function: Severity of dyspnea, occurrence of orthopnea (shortness of breath when in supine position i.e. lying flat), and the use of mechanical ventilation for respiratory in sufficiency. These 3 parameters are combined to create the respiratory domain with a score of 0-12(where 12 is normal function). Although individual items and patients vary, ALSFRS-R typically declines at a relatively constant rate over time. Plotted over time the slope of the line obtained indicates the speed of progression and thus an effective treatment might be expected ro reduce the slope of decline.

    Time frame: Change from Baseline in respiratory function of ALSFRS-R at study completion (subject's last visit, 2-48 weeks after study entry)

  4. Need for Respiratory Support Device

    Time to respiratory device support (non invasive) or death

    Time frame: Time to event at study completion (subject's last visit, 2-48 weeks after study entry)

  5. Borg Category Ratio 10 Scale (CR 10)

    Patients rated their perception of the severity of their dyspnea using the Borg Category Ration 10 scale (CR 10). The scale ranges from 0(no dysponea) to 10 (maximal dyspnea). each category is numbered and most but not all have verbal cues. At each assessment the patient scored the category they felt best described their symptoms. The analysis measured change from baseline to the end of the study in both a supine and sitting position where a negative score indicates improvement and a positive score reflects worsening.

    Time frame: Baseline through study completion (week 2, week 4, month 3, month 6, end of study (subject's last visit, 2-48 weeks after study entry)

  6. Number of Subjects Requiring Health and Home Care Resource Use

    The number of study subjects requiring Health and home care resource use was aggregated over the course of the study for each subject and summarised using descriptive statistics.

    Time frame: Baseline through study completion (2- 48 weeks after study entry)

  7. Subject's Status for Tracheostomy and Survival

    Number of patients with the need for tracheostomy or who died whilst on treatment from baseline to the end of the study was summarised using descriptive statistics.

    Time frame: Baseline to end of study (average 2-48 weeks after study entry

  8. Health Care Service Use During the Study(Stays in Hospital)

    The number of night stays in hospital were recorded throughout the study using a diary given to the study subjects

    Time frame: From baseline to the end of the study(2-48 weeks after study entry)

  9. Health Care Service Use During the Study(Visits to the Emergency Room)

    The number of visits to the emergency room were recorded throughout the study using a diary given to the study subjects

    Time frame: From baseline to the end of the study(2-48 weeks after study entry)

  10. Health Care Service Use During the Study (Days Spent in an Institutional Facility)

    The number of days spent in an institutional facility were recorded throughout the study using a diary given to the study subjects

    Time frame: From baseline to the end of the study(2-48 weeks after study entry)

07

Results

Posted Mar 9, 2023

Participant flow

Patients with amyotrophic lateral sclerosis (ALS) who completed 48 weeks of treatment in the REFALS study (NCT03505021) were recruited

Participant flow — Overall Study
MilestoneLevosimendan
Started227
Completed0
Not completed227
Withdrew: Protocol violation1
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject2
Withdrew: Reason not known2
Withdrew: Personal reason14
Withdrew: Disease progression30
Withdrew: Adverse event12
Withdrew: Sponsor terminated study164

Outcome measures

PrimaryAdverse Events Recording

Adverse Events as subject counts and proportions (%) of subject per Adverse Event

Time frame:
From signing informed consent until 14-25 days after the last study treatment for all patients, an average of 23.5 weeks.
Reported as:
Count of participants · Participants
Adverse Events Recording
ParticipantsLevosimendan
Adverse Events Recording161
PrimaryPulse/Heart Rate Assessment

Actual values and changes from baseline in supine pre-dose pulse/heart rate were summarised using descriptive statistics .

Time frame:
Change in pulse and heart rate(from ECG recording) from Baseline, week 2, week 4, week 6 (pulse rate only), Month 3, Month 6, end of study (subject's last visit, 2-48 weeks after study entry)
Reported as:
Mean · beats per minute (bpm)
Pulse/Heart Rate Assessment
beats per minute (bpm)Levosimendan
Change in pulse rate at week 27.0 ± 8.8
Change in pulse rate at 4 weeks10.0 ± 10.4
Change in pulse rate at week 68.5 ± 12.0
chnage in pulse rate at Month 310.4 ± 10.6
Change in pulse rate at month 612.8 ± 10.6
Change in pulse rate at end-of-study3.5 ± 12.6
Change in Heart rate at week 29.1 ± 10.1
Change in Heart rate at week 412.8 ± 9.4
Change in heart rate at Month 312.6 ± 9.3
Change in heart rate at month 615.0 ± 9.9
Change in heart rate at end-of-study5.3 ± 10.9
Baseline supine pulse rate75.8 ± 12.5
Baseline supine heart rate73.5 ± 12.0
Primary12-lead Electrocardiogram Assessments

Summarisation of any abnormal 12-lead ECG findings using descriptive statistics.

Time frame:
Baseline, week 2, week 4, month 3, month 6, end-of-study(subject's last visit, 2-48 weeks after study entry)
Reported as:
Count of participants · Participants
12-lead Electrocardiogram Assessments
ParticipantsLevosimendan
Baseline abnormal ECG69
Week 2 abnormal ECG56
Week 4 abnormal ECG43
Month 3 abnormal ECG27
Month 6 abnormal ECG11
End-of study abnormal ECG36
SecondaryDisease Progression

Count of study withdrawals due to disease progression

Time frame:
From Baseline through study completion(subject's last visit, 2-48 weeks after study entry)
Reported as:
Count of participants · Participants
Disease Progression
ParticipantsLevosimendan
Total withdrawal due to sponsor terminating the study164
Number of withdrawals due to disease progression30
SecondarySupine Slow Vital Capacity (SVC)

Change from baseline in supine and sitting SVC (all devices) through to the end of the study, expressed as a % of predicted normal

Time frame:
The change from Baseline, week 2, week 4, month 3, month 6, end-of-study (subject's last visit, 2-48 weeks after study entry)
Reported as:
Mean · % of predicted normal
Supine Slow Vital Capacity (SVC)
% of predicted normalLevosimendan
Change from baseline in supine SVC at week 21.5 ± 7.2
Change from baseline in supine SVC at week 40.8 ± 10.2
Change from baseline in supine SVC at month 3-3.5 ± 10.4
Change from baseline in supine SVC at month 6-5.3 ± 13.2
Change from baseline in supine SVC at the end of the study-5.6 ± 17.4
Change from baseline in sitting SVC at week 21.4 ± 6.6
Change from baseline in sitting SVC at week 42.1 ± 9.8
Change from baseline in sitting SVC month 3-1.9 ± 11.9
Change from baseline in sitting SVC month 6-6.1 ± 12.4
Change from baseline in sitting SVC at the end of the study-7.3 ± 12.1
Baseline Supine SVC (% predicted normal54.4 ± 21.6
Baseline Sitting SVC (% predicted normal)61.4 ± 19.4
SecondaryRevised ALS Functional Rating Scale (ALSFRS-R)

ALSFRS-R scale contains 3 parameters related to respiratory function: Severity of dyspnea, occurrence of orthopnea (shortness of breath when in supine position i.e. lying flat), and the use of mechanical ventilation for respiratory in sufficiency. These 3 parameters are combined to create the respiratory domain with a score of 0-12(where 12 is normal function). Although individual items and patients vary, ALSFRS-R typically declines at a relatively constant rate over time. Plotted over time the slope of the line obtained indicates the speed of progression and thus an effective treatment might be expected ro reduce the slope of decline.

Time frame:
Change from Baseline in respiratory function of ALSFRS-R at study completion (subject's last visit, 2-48 weeks after study entry)
Reported as:
Mean · Score on a scale
Revised ALS Functional Rating Scale (ALSFRS-R)
Score on a scaleLevosimendan
Change from baseline in respiratory function ALSFR-S at end of study-1.2 ± 2.3
Baseline respiratory ALSFRS-R9.4 ± 3.0
SecondaryNeed for Respiratory Support Device

Time to respiratory device support (non invasive) or death

Time frame:
Time to event at study completion (subject's last visit, 2-48 weeks after study entry)
Reported as:
Mean · days
Need for Respiratory Support Device
daysLevosimendan
Need for Respiratory Support Device259.5 ± 10.46
SecondaryBorg Category Ratio 10 Scale (CR 10)

Patients rated their perception of the severity of their dyspnea using the Borg Category Ration 10 scale (CR 10). The scale ranges from 0(no dysponea) to 10 (maximal dyspnea). each category is numbered and most but not all have verbal cues. At each assessment the patient scored the category they felt best described their symptoms. The analysis measured change from baseline to the end of the study in both a supine and sitting position where a negative score indicates improvement and a positive score reflects worsening.

Time frame:
Baseline through study completion (week 2, week 4, month 3, month 6, end of study (subject's last visit, 2-48 weeks after study entry)
Reported as:
Mean · units on a scale
Borg Category Ratio 10 Scale (CR 10)
units on a scaleLevosimendan
Baseline in Borg score Supine position2.52 ± 2.62
Change from baseline in Borg score supine at week 20.15 ± 2.16
chenge from baseline in Borg score week 40.40 ± 2.21
Change from baseline in Borg score supine at month 30.54 ± 2.05
Change from baseline in Borg score supine at month 61.61 ± 2.07
Change from baseline in Borg score supine at end of study1.58 ± 2.78
Baseline Borg score sitting2.19 ± 2.33
Change from baseline in Borg score sitting at week 20.01 ± 1.71
Change from baseline in Borg score sitting at week 40.34 ± 1.94
Change from baseline in Borg score sitting at month 30.61 ± 2.08
Change from baseline in Borg score sitting month 61.2 ± 1.87
Change from baseline in Borg score sitting at end of study1.07 ± 2.54
SecondaryNumber of Subjects Requiring Health and Home Care Resource Use

The number of study subjects requiring Health and home care resource use was aggregated over the course of the study for each subject and summarised using descriptive statistics.

Time frame:
Baseline through study completion (2- 48 weeks after study entry)
Reported as:
Count of participants · Participants
Number of Subjects Requiring Health and Home Care Resource Use
ParticipantsLevosimendan
Number of Subjects Requiring Health and Home Care Resource Use95
SecondarySubject's Status for Tracheostomy and Survival

Number of patients with the need for tracheostomy or who died whilst on treatment from baseline to the end of the study was summarised using descriptive statistics.

Time frame:
Baseline to end of study (average 2-48 weeks after study entry
Reported as:
Count of participants · Participants
Subject's Status for Tracheostomy and Survival
ParticipantsLevosimendan
Number of participants who died from baseline to end of the study treatment5
Number of participants requiring tracheostomy from baseline to the end of the study treatment0
SecondaryHealth Care Service Use During the Study(Stays in Hospital)

The number of night stays in hospital were recorded throughout the study using a diary given to the study subjects

Time frame:
From baseline to the end of the study(2-48 weeks after study entry)
Reported as:
Mean · Nights
Health Care Service Use During the Study(Stays in Hospital)
NightsLevosimendan
Health Care Service Use During the Study(Stays in Hospital)0.7 ± 2.7
SecondaryHealth Care Service Use During the Study(Visits to the Emergency Room)

The number of visits to the emergency room were recorded throughout the study using a diary given to the study subjects

Time frame:
From baseline to the end of the study(2-48 weeks after study entry)
Reported as:
Mean · visits
Health Care Service Use During the Study(Visits to the Emergency Room)
visitsLevosimendan
Health Care Service Use During the Study(Visits to the Emergency Room)0.1 ± 0.4
SecondaryHealth Care Service Use During the Study (Days Spent in an Institutional Facility)

The number of days spent in an institutional facility were recorded throughout the study using a diary given to the study subjects

Time frame:
From baseline to the end of the study(2-48 weeks after study entry)
Reported as:
Mean · days
Health Care Service Use During the Study (Days Spent in an Institutional Facility)
daysLevosimendan
Health Care Service Use During the Study (Days Spent in an Institutional Facility)4.7 ± 28.2

Adverse events

Collected over From signing informed consent until 14-25 days after the last study treatment administration, an average of 23.5 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levosimendan19/227 (8.4%)44/227 (19.4%)215/227 (94.7%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventLevosimendan
Respiratory failureRespiratory, thoracic and mediastinal disorders11/227
PneumoniaInfections and infestations4/227
DysponeaRespiratory, thoracic and mediastinal disorders2/227
Urinary Tract InfectionInfections and infestations2/227
Stoma Site PainInjury, poisoning and procedural complications2/227
FallInjury, poisoning and procedural complications2/227
Back PainMetabolism and nutrition disorders2/227
Respiratory distressRespiratory, thoracic and mediastinal disorders1/227
ChokingRespiratory, thoracic and mediastinal disorders1/227
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/227
Most frequent other events
Showing 10 of 22
Most frequent other events
EventLevosimendan
FallInjury, poisoning and procedural complications25/227
HeadacheNervous system disorders20/227
TachycardiaCardiac disorders18/227
DysponeaRespiratory, thoracic and mediastinal disorders14/227
Respiratory FailureRespiratory, thoracic and mediastinal disorders13/227
Heart Rate IncreasedInvestigations12/227
DysphagiaGastrointestinal disorders11/227
ConstipationGastrointestinal disorders10/227
NasopharyngitisInfections and infestations10/227
DiarrhoeaGastrointestinal disorders9/227

Baseline characteristics

Intention-to-Treat (ITT) including all randomised subjects was used for the primary evaluation.

Age, Categorical
Age, Categorical(Participants)Levosimendan
<=18 years0
Between 18 and 65 years160
>=65 years67
Sex: Female, Male
Sex: Female, Male(Participants)Levosimendan
Female85
Male142
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Levosimendan
Hispanic or Latino3
Not Hispanic or Latino224
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Levosimendan
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White218
More than one race0
Unknown or Not Reported9
08

Study locations

79 sites
  • Neuromuscular research Centre and Neuromuscular Clinic of Arizona
    Phoenix, Arizona 85028, United States
  • University of California San Diego
    La Jolla, California 92037-0886, United States
  • University of California Irvine Medical Center
    Orange, California 92868, United States
  • Hospital for Special Care
    New Britain, Connecticut 06053, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • The George Washington Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Holy Cross Hospital Neuroscience Institute
    Fort Lauderdale, Florida 33308, United States
  • University of Florida McKnight Brain Institute
    Gainesville, Florida 32611, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • University of South Florida/USF Health
    Tampa, Florida 33612, United States
  • Augusta University, Medical Centre
    Augusta, Georgia 30912, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan, Michigan Medicine University Hospital
    Ann Arbor, Michigan 48109, United States
  • Health Partners Speciality Center
    Saint Paul, Minnesota 55130-5302, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Neurology Associates
    Lincoln, Nebraska 68506, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Columbia Presbyterian Hospital
    New York, New York 10032, United States
  • Neurosciences Institute - Neurology Charlotte
    Charlotte, North Carolina 28207, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157-1023, United States
  • The Ohio State University Wexner Medical center
    Columbus, Ohio 43210, United States
  • Oregon Health and Science University
    Portland, Oregon 97201-3098, United States
  • Providence Brain and Spine Institute
    Portland, Oregon 97213, United States
  • Alleghenay General hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Nerve and Muscle Centre of Texas
    Houston, Texas 77030, United States
  • University of Utah Health-Imaging & Neurosciences Center in research Park
    Salt Lake City, Utah 84132, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Brain and Mind Centre
    Camperdown, New South Wales 2050, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Calvary Health Care Bethlehem
    Parkdale, Victoria 3195, Australia
  • Perron Institute for Neurological and Translational Science
    Nedlands, Western Australia 6009, Australia
  • Medizinische Universitat Innsbruck
    Innsbruck, Tyrol 6020, Austria
  • Salzqammergut-klinikum Vocklabruck, Neurologie
    Vocklabruck, Upper Austria 4840, Austria
  • Medizinische Universitat wein Universitatsklinik ffur Neurologie
    Wein, 1090, Austria
  • Algemeen Ziekenhuis St Lucas Gent
    Gent, 9000, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Regional de la Vitadelle
    Liège, 4000, Belgium
  • Alberta Health Services-Neuromuscular Clinic
    Calgary, Alberta T3M 1M4, Canada
  • University of Alberta, Division of Neurology
    Edmonton, Alberta T6G 2G3, Canada
  • Stan Cassidy Centre for Rehabilitation
    Fredericton, New Brunswick E3B 0C7, Canada
  • McMaster University Medical Centre
    Hamilton, Ontario L8N 3Z5, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Montreal Neurological Institute and Hospital
    Montréal, Quebec H3A 2B4, Canada
  • Centre Hospitalier Affilie Universitaire de Quebec
    Québec, Quebec G1J 1Z4, Canada
  • Helsinki University Central Hospital, Neurology Outpatients Clinic
    Helsinki, 00029, Finland
  • Turku University Hospital
    Turku, 20521, Finland
  • Centre Hospitalier Universitaire de Limoges Service de Neurologie
    Limoges, France
  • Hopital Gui de Chauliac Service de Neurologie
    Montpellier, 34295, France
  • Hopital Pasteur Centre de reference des Malades Neuromusculaires et SLA
    Nice, 06202, France
  • Charite Universitatmedizin Berlin- Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitatsklinikum Jena, Klinik fur Neurologie
    Jena, 07747, Germany
  • Universitatsklinikum Munster, Institut fur Schalfmedizin und Neuromuskalaire Erkrankungen
    Münster, 48149, Germany
  • Universitatsmedizin Rostock, Klinik und Poliklinik fuer Neurologie
    Rostock, 18147, Germany
  • Universitatsklinikum Ulm, Poliklinik fur Neurologie
    Ulm, 89081, Germany
  • Deutsche Klinik fur Daignostik
    Wiesbaden, 65191, Germany
  • Beaumont Hospital, Clinical Research Centre
    Dublin, Ireland
  • Azienda Policlinico San Martino
    Genova, 16132, Italy
  • ICS Maugeri Spa S UO Riabilitazione Nurologica
    Milan, 20138, Italy
  • Azienda Ospedaliera Universitaria-maggiore della Carita di Novara
    Novara, 28100, Italy
  • Azienda Ospedaliero Universitaria Pisana Ospedale Santa Chiara
    Pisa, 56126, Italy
  • Policlinico Umberto I di Roma Clinica Neurologica
    Rome, 00161, Italy
  • Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Univeritair Medisch Centrum Utrech
    Utrecht, 3584, Netherlands
  • Hospital Universitari de Bellvitge
    Barcelona, 08207, Spain
  • Hospital Universitario de Basurto
    Bilbao, 48013, Spain
  • Hospital Universitario Reina Sofia Servicio Neurologia
    Córdoba, 14011, Spain
  • Hospital San Rafael
    Madrid, 28016, Spain
  • Hospital Universitario y Politecnico de La Fe
    Valencia, 46026, Spain
  • Karlstad Central Hospital Neurology and Rehabilitation
    Karlstad, Sweden
  • Karolinska University Horpital Huddinge Neurology Clinic
    Stockholm, 14186, Sweden
  • Norrlanda University Hospital Neuro-huvud-hals-centrum Vasterbotten
    Umeå, 90185, Sweden
  • The Walton Centre NHs Foundation Trust, Neurology and Neurosurgery
    Liverpool, L9 7LJ, United Kingdom
  • Barts Health NHS Trust Royal London hospital
    London, E1 1BB, United Kingdom
09

References and documents

Publications

  • Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamaki M, Garratt C, Al-Chalabi A; REFALS investigators. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2021 Oct;20(10):821-831. doi: 10.1016/S1474-4422(21)00242-8. PubMed 34536404 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Nov 2020, 16 months.

Results were first posted in Mar 2023, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2019
First posted
May 13, 2019
StartActual
Jun 26, 2019
Primary completionActual
Nov 18, 2020
CompletionActual
Nov 18, 2020
Results first posted
Mar 9, 2023
Last update
Mar 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03948178
Responsible party
Sponsor
First posted
May 13, 2019
Start date
Jun 26, 2019
Primary completion
Nov 18, 2020
Completion
Nov 18, 2020
Results posted
Mar 9, 2023
Last update
Mar 9, 2023

Study contacts

Geneviève Nadeau, CSD
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simendan

Start the discussion